August’s Abusive Act Reflected In Sara Gruen’s Water For Elephants Novel (2006): A Psychoanalytic Critisism

The research is proposed to analyze how August‟s abusive act reflected in Water for Elephants novel by Psychoanalytic Criticism. There are two objectives: the first is to analyze the novel based on its structural elements and technical elements, and the second is to analyze the main character's personality using a psychoanalytic approach. This study is a qualitative study, using Sara Gruen‟s Water for Elephant novel 2006 as of structural elements, and the secondary data. The primary data source is Water for Elephants novel which is written by Sara Gruen , and the secondary data are some articles, book of literary and internet related to the subject. The method of collecting data in this research is library research by reading some related books and articles, accessing internet, taking notes of important parts, arranging, and drawing conclusion the data. In analyzing the data, the writer employs descriptive analysis. The results showed that this novel illustrates how abusive towards fellow human beings will make us lose the people we love. One thing that can destroy human‟s dreams is abusive. Thus, in order to keep away from abusive acts is caring and loving people around

Breathing Easy: Lung Health and Associated Conditions in the Day Care Setting

Introduction: Air pollutants are associated with many health risks. Children in the day care environment are uniquely suscept-ible to lung damage, infection, systemic illness & pollutant triggered hypersensitivity reactions. The latest public report by the CDC reports Vermont’s (VT) asthma rate is the high-est in the country at 11.1%. This project compared VT’s day care regulations regarding specific environmental factors linked with health risks to regulations in six surrounding New England states. We sought to assess whether VT’s regulations adequately protect children in day carehttps://scholarworks.uvm.edu/comphp_gallery/1064/thumbnail.jp

Systematic review and independent validation of genetic factors of radiographic outcome in rheumatoid arthritis identifies a genome-wide association with CARD9

OBJECTIVES: This study aimed to investigate non-HLA genetic mechanisms underlying radiographic severity in rheumatoid arthritis (RA).METHODS: A systematic review of publications reporting non-HLA genetic associations with radiographic severity in RA across ancestries was undertaken. Experimental validation was performed in the Norfolk Arthritis Register, comprising 1407 patients with available genetic and treatment data followed prospectively for up to 10 years, with 2198 longitudinal radiographs. Genome-wide genotyping was performed with Illumina Human Core Exome Array. Radiographic outcomes (presence of erosions; Larsen score) were modelled longitudinally. Fine mapping and functional annotations to refine associations to potential causative loci were undertaken using FUMA, PolyPhen2, and RegulomeDB.RESULTS: The systematic review identified 102 publications reporting 139 independent associations with radiographic outcome. Association with 15 independent polymorphisms were replicated in the Norfolk Arthritis Register data set, implicating adaptive immune processes (Th1, Th2, and Th17 pathways), cytokine regulation, and osteoclast differentiation. Notably, we refined the association of rs59902911 at the CARD9 locus to an intronic polymorphism within an active enhancer (rs78892335), achieving genome-wide significance and with an effect size exceeding the minimal clinically important difference for each copy of the minor allele (4.78 Larsen units/copy; 95% CI, 3.15-6.41; p = 9.01 × 10 -9). This polymorphism is associated with the expression of CARD9 in immune cells, including B cells. CONCLUSIONS: We provide a comprehensive list of validated genetic associations with RA outcome and demonstrate that non-HLA polymorphisms can associate with radiographic severity independently of disease susceptibility. This highlights the importance of dedicated genetic outcome studies for patient stratification in precision medicine for RA.</p

Comparison of clinical features between patients with anti-synthetase syndrome and dermatomyositis: Results from the MYONET registry.

OBJECTIVES To compare clinical characteristics, including the frequency of cutaneous, extramuscular manifestations, and malignancy, between adults with anti-synthetase syndrome (ASyS) and dermatomyositis (DM). METHODS Using data regarding adults from the MYONET registry, a cohort of DM patients with anti-Mi2/-TIF1ɣ/-NXP2/-SAE/-MDA5 autoantibodies, and a cohort of ASyS patients with anti-tRNA synthetase autoantibodies (anti-Jo1/-PL7/-PL12/-OJ/-EJ/-Zo/-KS) were identified. Patients with DM sine dermatitis or with discordant dual autoantibody specificities were excluded. Sub-cohorts of patients with ASyS with or without skin involvement were defined based on presence of DM-type rashes (heliotrope rash, Gottron's papules/sign, violaceous rash, shawl sign, V sign, erythroderma, and/or periorbital rash). RESULTS In total 1,054 patients were included (DM, n = 405; ASyS, n = 649). In ASyS cohort, 31% (n = 203) had DM-type skin involvement (ASyS-DMskin). A higher frequency of extramuscular manifestations, including Mechanic's hands, Raynaud's phenomenon, arthritis, interstitial lung disease, and cardiac involvement differentiated ASyS-DMskin from DM (all p< 0.001), whereas higher frequency of any of four DM-type rashes: heliotrope rash (n = 248, 61% vs n = 90, 44%), violaceous rash (n = 166, 41% vs n = 57, 9%), V sign (n = 124, 31% vs n = 28, 4%), and shawl sign (n = 133, 33% vs n = 18, 3%) differentiated DM from ASyS-DMskin (all p< 0.005). Cancer-associated myositis (CAM) was more frequent in DM (n = 67, 17%) compared with ASyS (n = 21, 3%) and ASyS-DMskin (n = 7, 3%) cohorts (both p< 0.001). CONCLUSION DM-type rashes are frequent in patients with ASyS; however, distinct clinical manifestations differentiate these patients from classical DM. Skin involvement in ASyS does not necessitate increased malignancy surveillance. These findings will inform future ASyS classification criteria and patient management

The CASTOR mission

CASTOR is a proposed wide-field ( 30 ′ × 30 ′ = 0.25 deg 2 ), high-resolution ( FWHM ∼ 0.15 ′′ ), 1-m-diameter space telescope that is under development by the Canadian Space Agency and the National Research Council of Canada. Optimized for UV/blue-optical wavelengths, the telescope uses dichroics to enable imaging in three channels (and up to five bands) that cover the 0.15 to 0.55 μ m spectral region, simultaneously. CASTOR will also feature low- and low-medium-resolution spectroscopic capabilities through the use of a deployable grism for low-resolution ( R ≲ 420 ) slit-less spectroscopy in its UV and u channels, and low-medium-resolution R ∼ 1400 multi-object spectroscopy in a parallel field using a digital micro-mirror device. High-speed, precision photometry will be possible using dedicated CMOS detectors in each of its three channels. We present an overview of the mission, including the optical design, instruments and detectors, payload layout, satellite bus, orbit, and ground segment. We describe the mission’s scientific capabilities and expected place within the astronomical landscape in the 2030s. The 5-year lifetime is baselined on a combination of legacy surveys, guest observer programs, and target-of-opportunity science. We summarize scientific plans for the mission in each of eight fields: cosmology, time domain and multi-messenger science, active galactic nuclei, galaxies, near-field cosmology, stellar astrophysics, exoplanets, and solar system studies. We conclude by describing ongoing development efforts, highlighting areas of particular relevance for NASA’s Habitable Worlds Observatory

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome